Dual inhibition of sirtuins 1 and 2: reprogramming metabolic energy dynamics in chronic myeloid leukemia as an immunogenic anticancer strategy

Michael Schnekenburger; Anne Lorant; Sruthi Reddy Gajulapalli; Ridhika Rajora; Jin-Young Lee; Aloran Mazumder; Haeun Yang; Christo Christov; Hyoung Jin Kang; Bernard Pirotte; Marc Diederich

doi:10.1002/cac2.12590

Cancer Communications ›› 2024, Vol. 44 ›› Issue (08) : 915 -920. DOI: 10.1002/cac2.12590

LETTER TO THE JOURNAL

Dual inhibition of sirtuins 1 and 2: reprogramming metabolic energy dynamics in chronic myeloid leukemia as an immunogenic anticancer strategy

Author information +

History +

PDF

Cite this article

Download citation ▾

Michael Schnekenburger, Anne Lorant, Sruthi Reddy Gajulapalli, Ridhika Rajora, Jin-Young Lee, Aloran Mazumder, Haeun Yang, Christo Christov, Hyoung Jin Kang, Bernard Pirotte, Marc Diederich. Dual inhibition of sirtuins 1 and 2: reprogramming metabolic energy dynamics in chronic myeloid leukemia as an immunogenic anticancer strategy. Cancer Communications, 2024, 44(08): 915-920 DOI:10.1002/cac2.12590

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Koschmieder S, Vetrie D. Epigenetic dysregulation in chronic myeloid leukaemia: A myriad of mechanisms and therapeutic options. Semin Cancer Biol. 2018; 51: 180–197.

[2]	Kuntz EM, Baquero P, Michie AM, Dunn K, Tardito S, Holyoake TL, et al. Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells. Nat Med. 2017; 23(10): 1234–1240.

[3]	Wu QJ, Zhang TN, Chen HH, Yu XF, Lv JL, Liu YY, et al. The sirtuin family in health and disease. Signal Transduct Target Ther. 2022; 7(1): 402.

[4]	Carafa V, Altucci L, Nebbioso A. Dual Tumor Suppressor and Tumor Promoter Action of Sirtuins in Determining Malignant Phenotype. Front Pharmacol. 2019; 10: 38.

[5]	Chen G, Huang P, Hu C. The role of SIRT2 in cancer: A novel therapeutic target. Int J Cancer. 2020; 147(12): 3297–3304.

[6]

Schnekenburger M, Goffin E, Lee JY, Jang JY, Mazumder A, Ji S, et al. Discovery and Characterization of R/S-N-3-Cyanophenyl-N’-(6-tert-butoxycarbonylamino-3, 4-dihydro-2, 2-dimethyl-2H-1-benzopyran-4-yl)urea, a New Histone Deacetylase Class III Inhibitor Exerting Antiproliferative Activity against Cancer Cell Lines. J Med Chem. 2017; 60(11): 4714–4733.

[7]	de Beauchamp L, Himonas E, Helgason GV. Mitochondrial metabolism as a potential therapeutic target in myeloid leukaemia. Leukemia. 2022; 36(1): 1–12.

[8]	Diepstraten ST, Anderson MA, Czabotar PE, Lessene G, Strasser A, Kelly GL. The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs. Nat Rev Cancer. 2022; 22(1): 45–64.

[9]	Kroemer G, Galassi C, Zitvogel L, Galluzzi L. Immunogenic cell stress and death. Nat Immunol. 2022; 23(4): 487–500.

[10]	Fucikova J, Kepp O, Kasikova L, Petroni G, Yamazaki T, Liu P, et al. Detection of immunogenic cell death and its relevance for cancer therapy. Cell Death Dis. 2020; 11(11): 1013.